Growth Hormone•Selective GHRP
📈Ipamorelin
Selective GH secretagogue. Stimulates GH release without elevating cortisol or prolactin — cleaner GH stimulus than older GHRPs. Stack with CJC-1295 for synergistic GH amplification.
Amino acids
5 (pentapeptide)
Mol. weight
711.9 Da
Half-life
~2 hours
Availability
On inquiry
Amino acid sequence
Aib-His-D-2Nal-D-Phe-Lys-NH₂What Is Ipamorelin?
Ipamorelin is a selective pentapeptide growth hormone releasing peptide (GHRP) that agonises the GHSR-1a (ghrelin receptor) in the pituitary and hypothalamus. Unlike GHRP-6 and GHRP-2, ipamorelin does not significantly elevate cortisol, ACTH, or prolactin — making it the cleanest GHRP for research use.
Key Mechanisms
- GHSR-1a agonism — stimulates pituitary GH secretion in a dose-dependent manner
- Pulse frequency increase — increases the frequency of natural GH pulses without disrupting the pulsatile pattern
- Ghrelin-independent selectivity — no significant cortisol or prolactin release at research doses
Key References
- Raun K et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol, 1998;139:552–561.
Related in Growth Hormone
📈GHRH Analogue
CJC-1295
Long-acting GHRH analogue. Stimulates pituitary GH release in pulses. Combined with Ipamorelin for synergistic GH secretion. DAC (Drug Affinity Complex) extends half-life from 30 min to 6–8 days.
📈FDA Approved
HGH Somatropin
Recombinant human growth hormone (191 aa). The upstream GH/IGF-1 axis activator. FDA-approved since 1985. Drives body composition, bone density, wound healing and metabolic function via JAK2/STAT5b.
📈Anabolic Effector
IGF-1 LR3
Long-acting IGF-1 analogue with 20–30h half-life. Activates mTORC1, suppresses FOXO atrophy genes, and drives satellite cell proliferation. 1000× reduced IGFBP binding vs native IGF-1.